WO2005040829A3 - Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17) - Google Patents
Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17) Download PDFInfo
- Publication number
- WO2005040829A3 WO2005040829A3 PCT/EP2004/011405 EP2004011405W WO2005040829A3 WO 2005040829 A3 WO2005040829 A3 WO 2005040829A3 EP 2004011405 W EP2004011405 W EP 2004011405W WO 2005040829 A3 WO2005040829 A3 WO 2005040829A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- disorders
- diseases
- gpr17
- therapeutics
- diagnostics
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57423—Specifically defined cancers of lung
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03023856 | 2003-10-21 | ||
EP03023856.2 | 2003-10-21 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005040829A2 WO2005040829A2 (en) | 2005-05-06 |
WO2005040829A3 true WO2005040829A3 (en) | 2005-06-23 |
Family
ID=34486088
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/011405 WO2005040829A2 (en) | 2003-10-21 | 2004-10-12 | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17) |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005040829A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20042007A1 (en) | 2004-10-21 | 2005-01-21 | Consiglio Nazionale Ricerche | "GPR17 RECIPE MODULATORS AND THEIR THERAPEUTIC USES" |
US9309514B2 (en) | 2012-01-28 | 2016-04-12 | The Trustees Of Columbia University In The City Of New York | G protein-coupled purinergic receptor Gpr17 mediates orexigenic effects of FoxO1 in AgRP neurons |
CN113667738A (en) * | 2021-08-25 | 2021-11-19 | 中国医科大学附属第一医院 | Receptor protein GPR17 for diagnosing leucoderma diseases and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996039438A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | G-protein receptor hibeb69 |
US5759804A (en) * | 1992-11-17 | 1998-06-02 | Icos Corporation | Isolated nucleic acid encoding seven transmembrane receptors |
WO2000022129A1 (en) * | 1998-10-13 | 2000-04-20 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human g protein-coupled receptors |
WO2001068842A2 (en) * | 2000-03-14 | 2001-09-20 | Bayer Aktiengesellschaft | Regulation of human p2y-like gpcr protein |
GB2360586A (en) * | 2000-02-18 | 2001-09-26 | Glaxo Group Ltd | Assays for and modulators of cysteinyl leukotriene-like receptors |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
-
2004
- 2004-10-12 WO PCT/EP2004/011405 patent/WO2005040829A2/en active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5759804A (en) * | 1992-11-17 | 1998-06-02 | Icos Corporation | Isolated nucleic acid encoding seven transmembrane receptors |
WO1996039438A1 (en) * | 1995-06-06 | 1996-12-12 | Human Genome Sciences, Inc. | G-protein receptor hibeb69 |
WO2000022129A1 (en) * | 1998-10-13 | 2000-04-20 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human g protein-coupled receptors |
GB2360586A (en) * | 2000-02-18 | 2001-09-26 | Glaxo Group Ltd | Assays for and modulators of cysteinyl leukotriene-like receptors |
WO2001068842A2 (en) * | 2000-03-14 | 2001-09-20 | Bayer Aktiengesellschaft | Regulation of human p2y-like gpcr protein |
WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
Also Published As
Publication number | Publication date |
---|---|
WO2005040829A2 (en) | 2005-05-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005106492A3 (en) | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 3 (ccr3) | |
WO2004104215A3 (en) | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase 7 (dpp7) | |
WO2005095973A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) | |
WO2005040828A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49) | |
WO2005050225A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84) | |
WO2005118840A3 (en) | Diagnostics and therapeutics for diseases associated with kallikrein 10 (klk10) | |
WO2005040829A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 17 (gpr17) | |
WO2004099782A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor gpr39 (gpr39) | |
WO2005074969A3 (en) | Diagnostics and therapeutics for diseases associated with human nuclear receptor nr4a1 (nr4a1) | |
WO2005040211A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1) | |
WO2005059546A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35) | |
WO2005040825A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20) | |
WO2004106935A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103) | |
WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
WO2005095984A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled alpha 2a-adrenoceptor (adra2a) | |
WO2004099783A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor ltb4 (ltb4) | |
WO2004104574A3 (en) | Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7) | |
WO2004099781A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor rdc1 (rdc1) | |
WO2005108998A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor beta-3 adreno (adrb3) | |
WO2005059504A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor gpr34 (gpr34) | |
WO2004082571A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 86 (gpr86) | |
WO2005040824A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 24 (gpr24) | |
WO2004099248A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2) | |
WO2006008009A3 (en) | Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6) | |
WO2005103711A3 (en) | Diagnostics and therapeutics for diseases associated with cxc chemokine receptor 1 (cxcr1) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |